Sources indicate that Permira is currently in discussions with advisers, and the sale process might commence by the end of this year.
Nevertheless, the talks are still in the initial phase, and Permira might choose to keep the business.
Neuraxpharm focuses on creating and marketing medications for chronic neurological and psychiatric disorders, such as epilepsy, Parkinson's disease, Alzheimer's disease, multiple sclerosis, depression, and psychosis. A significant asset for the company is the multiple sclerosis medication BRIUMVI.
In 2020, Permira purchased Neuraxpharm for an undisclosed amount.
source: bloomberg.com
Nevertheless, the talks are still in the initial phase, and Permira might choose to keep the business.
Neuraxpharm focuses on creating and marketing medications for chronic neurological and psychiatric disorders, such as epilepsy, Parkinson's disease, Alzheimer's disease, multiple sclerosis, depression, and psychosis. A significant asset for the company is the multiple sclerosis medication BRIUMVI.
In 2020, Permira purchased Neuraxpharm for an undisclosed amount.
source: bloomberg.com
